​

Apogee Therapeutics (APGE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

APGE Stock Forecast

Apogee Therapeutics (APGE) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $108.86, with a high of $137.00 and a low of $83.00. This represents a 51.40% increase from the last price of $71.90.

- $30 $60 $90 $120 $150 High: $137 Avg: $108.86 Low: $83 Last Closed Price: $71.9

APGE Stock Rating

Apogee Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

APGE Price Target Upside V Benchmarks

TypeNameUpside
StockApogee Therapeutics51.40%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-69
Avg Price Target-$109.83$103.44
Last Closing Price$71.90$71.90$71.90
Upside/Downside-52.75%43.87%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-142--16
Feb, 26-142--16
Jan, 26113---14
Dec, 25111---12
Nov, 25110---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 02, 2026Akash TewariJefferies$95.00$65.9943.96%32.13%
Jan 22, 2026RBC Capital$83.00$81.911.33%15.44%
Jan 07, 2026Craig-Hallum$116.00$78.2048.34%61.34%
Jan 06, 2026BTIG$137.00$76.7878.43%90.54%
Jan 06, 2026Stifel Nicolaus$133.00$76.3474.22%84.98%
Dec 16, 2025Stephens$95.00$74.7827.04%32.13%
Dec 09, 2025Deutsche Bank$103.00$74.7537.79%43.25%
Nov 03, 2025Craig-Hallum$109.00$56.6392.48%51.60%
Sep 25, 2025RBC Capital$60.00$37.5259.91%-16.55%
May 13, 2024Alex ThompsonStifel Nicolaus$95.00$52.7180.23%32.13%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 02, 2026RBC CapitalSector PerformSector Performhold
Feb 02, 2026JefferiesBuyBuyhold
Jan 25, 2026UBSBuyBuyhold
Jan 25, 2026CitigroupBuyBuyhold
Jan 22, 2026RBC CapitalOutperformSector Performdowngrade
Jan 07, 2026Craig-HallumBuyBuyhold
Jan 07, 2026Wolfe ResearchPeer Performinitialise
Jan 06, 2026BTIGBuyBuyhold
Dec 16, 2025StephensOverweightinitialise
Dec 09, 2025Deutsche BankBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.66$-3.30$-4.22---
Avg Forecast$-3.26$-3.10$-4.32$-5.36$-6.49$-7.03
High Forecast$-1.93$-2.90$-3.38$-3.52$-4.30$-7.03
Low Forecast$-3.85$-3.32$-4.77$-10.81$-12.46$-7.03
Surprise %-49.08%6.45%-2.31%---

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.98M$-182.15M----
Avg Forecast$-83.98M$-77.65M$-101.84M$-179.14M$-209.56M$-175.70M
High Forecast$-48.25M$-72.39M$-84.47M$-87.90M$-107.52M$-175.70M
Low Forecast$-96.19M$-82.91M$-119.20M$-270.39M$-311.60M$-175.70M
Surprise %-134.57%----

APGE Forecast FAQ

Is Apogee Therapeutics stock a buy?

Apogee Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Apogee Therapeutics is a favorable investment for most analysts.

What is Apogee Therapeutics's price target?

Apogee Therapeutics's price target, set by 7 Wall Street analysts, averages $108.86 over the next 12 months. The price target range spans from $83 at the low end to $137 at the high end, suggesting a potential 51.40% change from the previous closing price of $71.9.

How does Apogee Therapeutics stock forecast compare to its benchmarks?

Apogee Therapeutics's stock forecast shows a 51.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Apogee Therapeutics over the past three months?

  • March 2026: 0% Strong Buy, 87.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 87.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 7.14% Strong Buy, 92.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Apogee Therapeutics’s EPS forecast?

Apogee Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.36, marking a 27.01% increase from the reported $-4.22 in 2025. Estimates for the following years are $-6.49 in 2027, and $-7.03 in 2028.

What is Apogee Therapeutics’s revenue forecast?

Apogee Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, and $0 for 2028.

What is Apogee Therapeutics’s net income forecast?

Apogee Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-179M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-210M in 2027, and $-176M in 2028.